These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33823573)

  • 1. Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience.
    Dattilo G; Bitto R; Correale M; Morabito C; Vaccaro V; Laterra G; Casale M; Crea P; DI Bella G; Luzza F; Migliorato A; Katsiki N; DE Gregorio C
    Minerva Cardiol Angiol; 2022 Oct; 70(5):555-562. PubMed ID: 33823573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.
    Mapelli M; Mattavelli I; Paolillo S; Salvioni E; Magrì D; Galotta A; De Martino F; Mantegazza V; Vignati C; Esposito I; Dell'Aversana S; Paolillo R; Capovilla T; Tamborini G; Nepitella AA; Filardi PP; Agostoni P
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1173-1184. PubMed ID: 37368004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study.
    Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
    Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.
    Corrado E; Dattilo G; Coppola G; Morabito C; Bonni E; Zappia L; Novo G; de Gregorio C
    Eur J Clin Pharmacol; 2022 Jan; 78(1):19-25. PubMed ID: 34554274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor.
    Kim MJ; Jang HN; Song HN; Lee JS; Kang MG
    Intern Med; 2022 May; 61(10):1573-1576. PubMed ID: 34707049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
    Du H; Li X; Zhao W; Jiang N
    J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
    Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
    Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and feasibility of angiotensin receptor neprilysin inhibitor in real-world patients with acute decompensated heart failure.
    Rossini R; Angelini F; Giordana F; Coppini L; Ferraro I; Ruffino E; Varbella F; Tizzani E; Valente E; Musumeci G
    Minerva Cardiol Angiol; 2023 Jun; 71(3):266-274. PubMed ID: 36799543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome.
    Fröb EJ; Sindermann JR; Reinecke H; Tuleta I
    Adv Clin Exp Med; 2022 May; 31(5):475-487. PubMed ID: 35092651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
    Piña IL; Camacho A; Ibrahim NE; Felker GM; Butler J; Maisel AS; Prescott MF; Williamson KM; Claggett BL; Desai AS; Solomon SD; Januzzi JL;
    JACC Heart Fail; 2021 Jan; 9(1):42-51. PubMed ID: 33189630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    Hu J; Wu Y; Zhou X; Wang X; Jiang W; Huo J; Shan Q
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):445-451. PubMed ID: 33030857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
    Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test.
    Malfatto G; Ravaro S; Caravita S; Baratto C; Sorropago A; Giglio A; Tomaselli M; Parati G; Villani A
    Acta Cardiol; 2020 Dec; 75(8):732-736. PubMed ID: 31577528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.